Phase I dose-escalation study of docetaxel, nedaplatin, and 5-fluorouracil combination chemotherapy in patients with advanced esophageal cancer

被引：0
|
作者：
Tatsuya Miyazaki
Makoto Sohda
Naritaka Tanaka
Shigemasa Suzuki
Keisuke Ieta
Makoto Sakai
Akihiko Sano
Takehiko Yokobori
Takanori Inose
Masanobu Nakajima
Minoru Fukuchi
Hitoshi Ojima
Hiroyuki Kato
Hiroyuki Kuwano
机构：
[1] Gunma University Graduate School,Department of General Surgical Science (Surgery 1)
[2] Dokkyo Medical University,First Department of Surgery
来源：
Cancer Chemotherapy and Pharmacology | 2013年 / 71卷
关键词：
Docetaxel; Nedaplatin; 5-Fluorouracil; Chemotherapy; Esophageal cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
More effective protocols are needed for unresectable and recurrent esophageal cancer. Therefore, we conducted a phase I trial to establish the recommended dose of docetaxel, nedaplatin, and 5-fluorouracil (DNF) as combination chemotherapy. Fourteen patients with esophageal cancer were enrolled and received DNF combination therapy at different dose levels according to the treatment and examination plan. Dose-limiting toxicities (DLTs) included febrile neutropenia. DLTs occurred in 3/5 patients at level 4. The recommended doses (level 3) of DNF were 60 mg/m2 (day 1), 70 mg/m2 (day 1), and 700 mg/m2 (days 1–5), respectively, given at 3-week intervals. In conclusion, DNF combined chemotherapy for advanced esophageal cancer was associated with relatively minor adverse events and was safely administered at the recommended dose. A phase II study is now underway.
引用
收藏
页码：853 / 857
页数：4
相关论文
共 50 条
  • [21] Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours
    Van Cutsem, Eric
    Khayat, David
    Verslype, Chris
    Billemont, Bertrand
    Tejpar, Sabine
    Meric, Jean-Baptiste
    Soussan-Lazard, Karen
    Assadourian, Sylvie
    Cartot-Cotton, Sylvaine
    Rixe, Olivier
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (01) : 17 - 24
  • [22] A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer
    Yasushi Sato
    Tetsuji Takayama
    Tamotsu Sagawa
    Tetsuro Okamoto
    Koji Miyanishi
    Tsutomu Sato
    Hironobu Araki
    Satoshi Iyama
    Seiichiro Abe
    Kazuyuki Murase
    Rishu Takimoto
    Hisayasu Nagakura
    Masato Hareyama
    Junji Kato
    Yoshiro Niitsu
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 570 - 576
  • [23] A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer
    Sato, Yasushi
    Takayama, Tetsuji
    Sagawa, Tamotsu
    Okamoto, Tetsuro
    Miyanishi, Koji
    Sato, Tsutomu
    Araki, Hironobu
    Iyama, Satoshi
    Abe, Seiichiro
    Murase, Kazuyuki
    Takimoto, Rishu
    Nagakura, Hisayasu
    Hareyama, Masato
    Kato, Junji
    Niitsu, Yoshiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (05) : 570 - 576
  • [24] Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours
    Freyer, G.
    Isambert, N.
    You, B.
    Zanetta, S.
    Falandry, C.
    Favier, L.
    Trillet-Lenoir, V.
    Assadourian, S.
    Soussan-Lazard, K.
    Ziti-Ljajic, S.
    Fumoleau, P.
    BRITISH JOURNAL OF CANCER, 2012, 107 (04) : 598 - 603
  • [25] Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours
    G Freyer
    N Isambert
    B You
    S Zanetta
    C Falandry
    L Favier
    V Trillet-Lenoir
    S Assadourian
    K Soussan-Lazard
    S Ziti-Ljajic
    P Fumoleau
    British Journal of Cancer, 2012, 107 : 598 - 603
  • [26] A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
    LoRusso, Patricia M.
    Infante, Jeffrey R.
    Kim, Kevin B.
    Burris, Howard A., III
    Curt, Gregory
    Emeribe, Ugochi
    Clemett, Delyth
    Tomkinson, Helen K.
    Cohen, Roger B.
    BMC CANCER, 2017, 17
  • [27] Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors
    Isambert, Nicolas
    Freyer, Gilles
    Zanetta, Sylvie
    You, Benoit
    Fumoleau, Pierre
    Falandry, Claire
    Favier, Laure
    Assadourian, Sylvie
    Soussan-Lazard, Karen
    Ziti-Ljajic, Samira
    Trillet-Lenoir, Veronique
    CLINICAL CANCER RESEARCH, 2012, 18 (06) : 1743 - 1750
  • [28] A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with docetaxel in patients with advanced solid tumors
    Robert, F.
    Sandler, A.
    Schiller, J. H.
    Ilagan, J.
    Harper, K.
    Vermeulen, W.
    Liu, G.
    Tye, L.
    Chao, R.
    Verkh, L.
    Traynor, A.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3514S - 3515S
  • [29] A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
    Patricia M. LoRusso
    Jeffrey R. Infante
    Kevin B. Kim
    Howard A. Burris
    Gregory Curt
    Ugochi Emeribe
    Delyth Clemett
    Helen K. Tomkinson
    Roger B. Cohen
    BMC Cancer, 17
  • [30] Phase II Trial of 5-Fluorouracil, Docetaxel, and Nedaplatin (UDON) Combination Therapy for Recurrent or Metastatic Esophageal Cancer
    Ueda, Hiroto
    Kawakami, Hisato
    Nonagase, Yoshikane
    Takegawa, Naoki
    Okuno, Tatsuya
    Takahama, Takayuki
    Takeda, Masayuki
    Chiba, Yasutaka
    Tamura, Takao
    Nakagawa, Kazuhiko
    ONCOLOGIST, 2019, 24 (02): : 163 - +
12345